These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26303418)

  • 21. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising strategies: Combination of epigenetic inhibitors for cancer therapy.
    Gronemeyer H
    Int J Cancer; 2020 Nov; 147(10):2656-2657. PubMed ID: 32599650
    [No Abstract]   [Full Text] [Related]  

  • 23. Epigenetic Therapies and Potential Drugs for Treating Human Cancer.
    Lin SQ; Li X
    Curr Drug Targets; 2020; 21(11):1068-1083. PubMed ID: 32209040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trials with 'epigenetic' drugs: an update.
    Nebbioso A; Carafa V; Benedetti R; Altucci L
    Mol Oncol; 2012 Dec; 6(6):657-82. PubMed ID: 23103179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic therapy of cancer: past, present and future.
    Yoo CB; Jones PA
    Nat Rev Drug Discov; 2006 Jan; 5(1):37-50. PubMed ID: 16485345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
    Kumar A; Emdad L; Fisher PB; Das SK
    Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecular modulators of cancer-associated epigenetic mechanisms.
    Itoh Y; Suzuki T; Miyata N
    Mol Biosyst; 2013 May; 9(5):873-96. PubMed ID: 23511667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetics in cancer therapy and nanomedicine.
    Roberti A; Valdes AF; Torrecillas R; Fraga MF; Fernandez AF
    Clin Epigenetics; 2019 May; 11(1):81. PubMed ID: 31097014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic modulators as therapeutic targets in prostate cancer.
    Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
    Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current paradigms in epigenetic anticancer therapeutics and future challenges.
    Singh M; Kumar V; Sehrawat N; Yadav M; Chaudhary M; Upadhyay SK; Kumar S; Sharma V; Kumar S; Dilbaghi N; Sharma AK
    Semin Cancer Biol; 2022 Aug; 83():422-440. PubMed ID: 33766649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
    Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
    Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
    Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
    Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetics in radiotherapy: where are we heading?
    Smits KM; Melotte V; Niessen HE; Dubois L; Oberije C; Troost EG; Starmans MH; Boutros PC; Vooijs M; van Engeland M; Lambin P
    Radiother Oncol; 2014 May; 111(2):168-77. PubMed ID: 24861629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic agents in combined anticancer therapy.
    Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
    Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.